Hemp-Derived Cannabinoids Panel - CannMed 25 Innovation & Investment Summit скачать в хорошем качестве

Hemp-Derived Cannabinoids Panel - CannMed 25 Innovation & Investment Summit

Tags: Hemp-Dervied Cannabinoids, Derived Cannabinoids, HDCs, THCA, Hemp Products, Hemp Product Safety Moderator: Jean E. Smith-Gonnell ​ (‪@troutmanpepperlockellp‬) Panelists: Mark A. Scialdone, PhD (BetterChem Consulting) , Michelle Peace, PhD (‪@virginiacommonwealthuniversity‬), Mike Hennesy (‪@wanabrands9237‬) The rapid rise of hemp-derived cannabinoids (HDCs) has created a new space in cannabinoid research and commerce, offering new therapeutic potentials and market opportunities and controversies. This fast-growing sector also faces critical challenges, including significant gaps in state and federal regulations and the presence of irresponsible actors exploiting legal loopholes. These issues raise concerns about consumer safety, product integrity, and the long-term viability of the industry. This panel unites scientists, policymakers, and legal professionals to provide a comprehensive exploration of the HDC landscape, emphasizing both its promise and its pitfalls. Attendees will learn about the latest research on the pharmacology and therapeutic potential of HDCs, alongside a frank discussion of the risks posed by unregulated products, misleading marketing practices, and inconsistent quality standards. Learn More about CannMed: https://cannmedevents.com/ Sign Up for Our Newsletter: https://share.hsforms.com/1oi57oJDnRN... 0:00 Intro & Welcome 0:45 Panelist Introductions 5:20 Farm Bill Loopholes Explained 12:15 Chemistry of CBD Conversions 18:40 Safety & Public Health Concerns 25:10 Youth Access & Vaping Issues 33:00 Regulatory Gaps & State Bans 42:30 Industry Risks & Market Impact 51:15 Federal Legalization & Policy Outlook 54:00 Closing Thoughts & Takeaways The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.